after agreeing to join the study, you will sign an informed consent form and confirm that you meet the eligibility criteria for ocular myasthenia gravis.

the study staff will collect basic health information, conduct a physical examination, and review any current medications.

you will complete several questionnaires that measure eye muscle weakness and quality of life, including the mgii ocular score, mg-adl ocular score, mgsp ro ocular muscle weakness scale, and mg-qol15r.

blood samples may be taken to establish baseline laboratory values.

the results from these assessments will be used as reference points for later comparisons.

you will receive a single subcutaneous injection of the study medication rozanolixizumab at a dose of 840 mg.

the injection is administered under the skin by trained study personnel.

the exact schedule for subsequent doses will be defined by the study protocol.

approximately 43 days after the first injection, you will return for a study visit where the same questionnaires (mgii ocular score, mg-adl ocular score, mgsp ro ocular muscle weakness scale, mg-qol15r) are repeated to evaluate changes.

at each visit, the study team will check for any adverse events (side effects) and record their severity.

additional laboratory tests may be performed to monitor safety.

you will continue to receive the prescribed dose of rozanolixizumab by subcutaneous injection at intervals specified in the study plan.

each injection is followed by routine safety checks and repeated questionnaire assessments to track your condition over time.

any serious or concerning side effects will be evaluated promptly, and the study medication may be stopped if necessary.

when the study period ends or if you decide to withdraw, you will attend a final visit.

final assessments, including the same set of questionnaires and safety evaluations, will be performed.

the study medication will be discontinued, and all collected data will be finalized for analysis.